罗欣药业集团股份有限公司 关于合计持股5%以上股东协议 证券代码：002793 股票简称：罗欣药业 公告编号：2025-063 登录新浪财经APP 搜索【信披】查看更多考评等级 2025年7月，得怡成都的管理人得怡投资管理（北京）有限公司（代表"得怡成都"）、得怡恒佳与中珏 基金签署了《股份转让协议之补充协议》，受让方中珏基金承诺，自标的股份交割完成之日（以证券登 记结算机构完成过户登记为准）起18个月内，不以任何形式转让本次受让的股份。具体内容详见公司于 2025年7月10日刊登于巨潮资讯网（http://www.cninfo.com.cn）的《关于合计持股5%以上股东协议转让 公司部分股份进展暨签署补充协议的公告》。 二、本次股份协议转让过户登记完成情况 转让公司部分股份 完成过户登记的公告 公司合计持股5%以上股东成都得怡欣华股权投资合伙企业（有限合伙）、克拉玛依市得怡恒佳股权投 资有限合伙企业保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 罗欣药业集团股份有限公司（以下简称"公司""本公司"）于近日 ...

证券代码：002793 股票简称：罗欣药业 公告编号：2025-063 罗欣药业集团股份有限公司 关于合计持股 5%以上股东协议转让公司部分股份 完成过户登记的公告 公司合计持股 5%以上股东成都得怡欣华股权投资合伙企业（有限合伙）、克 拉玛依市得怡恒佳股权投资有限合伙企业保证向本公司提供的信息内容真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 罗欣药业集团股份有限公司（以下简称"公司""本公司"）于近日收到股 东通知，获悉公司合计持股 5%以上股东成都得怡欣华股权投资合伙企业（有限 合伙）（以下简称"得怡成都"）、克拉玛依市得怡恒佳股权投资有限合伙企业 （以下简称"得怡恒佳"）向上海中珏私募基金管理有限公司（代表"中珏中钜 增利一号私募证券投资基金"）（以下简称"中珏基金"）协议转让公司部分股 份事项已在中国证券登记结算有限责任公司办理完成过户登记手续，并取得《证 券过户登记确认书》。现将具体情况公告如下： 一、本次协议转让的基本情况 三、其他说明 市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范 运作》 ...

证券日报网讯 7月29日晚间，罗欣药业发布公告称，本次调整后，中泰证券关于罗欣药业重大资产重组 项目于持续督导期间的独立财务顾问主办人为高旭佳先生和张世邦先生。 （文章来源：证券日报） ...

Market Overview - The indices continued to rise collectively, with a significant drop in the morning followed by a recovery in sentiment in the afternoon [3] - The Shanghai Composite Index, Shenzhen Component Index, and ChiNext Index closed up by 0.33%, 0.64%, and 1.86% respectively, with over 3,000 stocks declining and more than 2,200 stocks rising [4] Optimizing Fertility - The "Implementation Plan for Childcare Subsidy System" was officially launched, providing annual subsidies of 3,600 yuan per child for children under three years old starting January 1, 2025 [8] - The fertility optimization sector saw a collective high opening but ended with a "high open low close" trend, with the sector rising by only 0.18% after an initial surge [9][10] - Stocks like Beiyinmei and Aiyingshi opened strongly but fell significantly, while stocks in the dairy sector also experienced a similar pattern [10] Yajiang Hydropower Station - The Yajiang Hydropower Station saw a rebound in the afternoon, with stocks like Xining Special Steel and Tibet Tianlu hitting the daily limit [15] - The Yajiang Hydropower concept stocks rose over 2% by the end of the day, indicating a recovery in investor interest [14] Stablecoin Sector - The stablecoin concept stocks experienced a partial rebound, with companies like Hengbao Co. and Sifang Jichuang showing strong performance [19] - The sector had been quiet for about two weeks but is now looking for a significant catalyst to revive interest [21] Guotou Intelligent - Guotou Intelligent saw a significant rise, closing up over 18.5%, attributed to news regarding a special action by the Internet Information Office [25] - The company is reportedly working on AI fraud prevention services, with a potential market space exceeding 120 billion yuan if it covers 1 billion smartphone users [28]

证券代码：002793 股票简称：罗欣药业 公告编号：2025-063 一、本次协议转让的基本情况 2024 年 11 月，得怡成都的管理人得怡投资管理（北京）有限公司（代表"得 怡成都"）、得怡恒佳与中珏基金签署了《股份转让协议》，得怡成都拟通过协 议转让的方式向中珏基金转让其持有的本公司无限售流通股 18,589,668 股；得怡 恒佳拟通过协议转让的方式向中珏基金转让其持有的本公司无限售流通股 35,789,757 股。本次协议转让后，中珏基金将持有本公司股份 54,379,425 股，占 本公司总股本比例 5.00%，成为本公司持股 5%以上股东。具体内容详见公司于 2024 年 11 月 21 日刊登于巨潮资讯网（http://www.cninfo.com.cn）的《关于合计 持股 5%以上股东拟协议转让公司股份暨权益变动的提示性公告》。 罗欣药业集团股份有限公司 关于合计持股 5%以上股东协议转让公司部分股份 完成过户登记的公告 公司合计持股 5%以上股东成都得怡欣华股权投资合伙企业（有限合伙）、克 拉玛依市得怡恒佳股权投资有限合伙企业保证向本公司提供的信息内容真实、准 确、完整，没有虚假记载、误 ...

证券代码：002793 股票简称：罗欣药业 公告编号：2025-064 罗欣药业集团股份有限公司 关于更换重大资产重组独立财务顾问主办人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 中泰证券股份有限公司（以下简称"中泰证券"）作为罗欣药业集团股份有 限公司（以下简称"公司""罗欣药业"）重大资产置换及发行股份购买资产项 目（以下简称"重大资产重组"）的独立财务顾问，中泰证券指派高旭佳、李帅 担任独立财务顾问主办人。截至本公告披露日，重大资产重组已实施完毕，法定 持续督导期至 2022 年 12 月 31 日。公司重大资产重组的业绩承诺补偿股份回购 注销事宜已于 2022 年内完成，鉴于未退还分红款的交易对方，其持有的所有限 售股份暂不解禁上市流通，中泰证券需要对相关事宜继续履行持续督导义务。 本次调整后，中泰证券关于罗欣药业重大资产重组项目于持续督导期间的独 立财务顾问主办人为高旭佳先生和张世邦先生。本次更换独立财务顾问主办人的 事项不会对公司的生产经营造成风险和影响。 特此公告。 罗欣药业集团股份有限公司董事会 2025 年 7 月 29 日 1 ...

Core Viewpoint - The chemical pharmaceutical sector experienced a significant increase of 2.47% on July 29, with Nanjing Pharmaceutical leading the gains [1] Group 1: Market Performance - The Shanghai Composite Index closed at 3609.71, up 0.33% [1] - The Shenzhen Component Index closed at 11289.41, up 0.64% [1] Group 2: Individual Stock Performance - Nanjing Pharmaceutical (681899) closed at 11.90, with a rise of 17.01% and a trading volume of 388,700 shares, totaling a transaction value of 417 million yuan [1] - Yuandong Biological (688513) closed at 65.92, up 15.45%, with a trading volume of 74,200 shares and a transaction value of 466 million yuan [1] - Microchip Biotech (688321) closed at 38.37, increasing by 12.85%, with a trading volume of 401,800 shares and a transaction value of 1.49 billion yuan [1] - Aoxiang Pharmaceutical (603229) closed at 10.54, up 10.02%, with a trading volume of 480,600 shares and a transaction value of 493 million yuan [1] - Asia-Pacific Pharmaceutical (002370) closed at 6.81, also up 10.02%, with a trading volume of 1,937,200 shares and a transaction value of 1.285 billion yuan [1] - Chenxin Pharmaceutical (603367) closed at 25.93, up 10.01%, with a trading volume of 160,000 shares and a transaction value of 413 million yuan [1] - Fuyuan Pharmaceutical (6801089) closed at 22.90, increasing by 9.99%, with a trading volume of 176,900 shares and a transaction value of 389 million yuan [1] - Nikan Pharmaceutical (688658) closed at 33.02, up 9.96%, with a trading volume of 118,700 shares and a transaction value of 376 million yuan [1] - Luoxin Pharmaceutical (002793) closed at 5.97, increasing by 9.94%, with a trading volume of 421,300 shares and a transaction value of 240 million yuan [1] - Frontier Biotech (688221) closed at 22.42, up 9.74%, with a trading volume of 471,400 shares and a transaction value of 1.023 billion yuan [1] Group 3: Capital Flow - The chemical pharmaceutical sector saw a net inflow of 1.295 billion yuan from main funds, while retail funds experienced a net outflow of 1.198 billion yuan [1] - Speculative funds recorded a net outflow of 97.108 million yuan [1]

证券代码：002793 证券简称：罗欣药业 公告编号：2025-062 罗欣药业集团股份有限公司 关于为控股子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 罗欣药业集团股份有限公司（以下简称"公司"）及控股子公司对外担保总 额超过最近一期经审计净资产 100%；公司及控股子公司担保金额超过上市公司 最近一期经审计净资产 50%，提请投资者充分关注担保风险。 一、担保情况概述 为满足日常生产经营及业务拓展资金需要，保证生产经营持续发展和业务顺 利开展，公司拟为其控股子公司山东罗欣药业集团股份有限公司（以下简称"山 东罗欣"）人民币 86,000 万元银行授信额度提供担保。公司分别于 2025 年 1 月 20 日、2025 年 2 月 7 日召开第五届董事会第二十二次会议、第五届监事会第十 九次会议及 2025 年第一次临时股东大会，审议通过了《关于为控股子公司提供 担保的议案》。具体内容详见公司于 2025 年 1 月 21 日刊登于巨潮资讯网 （http://www.cninfo.com.cn）的《关于为控股子公司提供担 ...

Core Viewpoint - The announcement details the pledge and release of shares by the controlling shareholder of Luoxin Pharmaceutical Group Co., Ltd., indicating changes in shareholding structure and potential implications for the company's financial health and governance [1][2]. Share Pledge Situation - Luoxin Holdings, the controlling shareholder, pledged 25,000,000 shares, accounting for 10.55% of its holdings and 2.30% of the total shares of the company [1]. - The purpose of the pledge is for capital turnover, with the pledge starting on July 17 and set to expire on an unspecified date [1]. Share Release Situation - Luoxin Holdings released 16,500,000 shares from pledge, which represents 6.96% of its holdings and 1.52% of the total shares of the company [1]. - The release occurred on August 18, with the shares previously pledged starting from an unspecified date [1]. Cumulative Pledge Situation - As of the announcement date, the total pledged shares by Luoxin Holdings and its concerted parties amount to 102,443,530 shares, which is 43.23% of the shares held by the controlling shareholder and 9.42% of the total shares of the company [2]. - The corresponding financing balance for these pledged shares is 172.5 million yuan [2]. Financial Health of Shareholders - The controlling shareholder and its concerted parties are reported to have a good credit status and possess the financial capability to repay the pledged amounts [2].

Financing and Guarantee Overview - The company plans to continue financing leasing business for its subsidiaries, with a total amount not exceeding 150 million RMB, authorized for a period of 12 months from the board's approval date [1][2] - The company and its subsidiaries intend to provide guarantees totaling up to 648 million RMB for the year 2025, which includes various forms of guarantees among subsidiaries [2][3] Guarantee Progress - The company has provided irrevocable joint liability guarantees for financing leases of 20 million RMB for Shandong Luoxin and 30 million RMB for Shandong Yuxin, within the approved limits [3][8] - After the guarantees, the total guarantee balance for Shandong Luoxin will be 1,164.82 million RMB, with a remaining guarantee capacity of 797.79 million RMB [3][8] - For Shandong Yuxin, the total guarantee balance will be 30 million RMB, with a remaining guarantee capacity of 81 million RMB [3][8] Financial Data of Subsidiaries - Shandong Luoxin reported total assets of 4,972.40 million RMB and total liabilities of 2,756.94 million RMB for the year 2024, with a net profit of -632.30 million RMB [5] - Shandong Yuxin reported total assets of 909.11 million RMB and total liabilities of 635.76 million RMB for the year 2024, with a net profit of -1,160.44 million RMB [6] Board's Opinion - The board believes that engaging in financing leasing will effectively meet the company's operational funding needs and optimize the capital structure [8] - The company maintains effective control over Shandong Luoxin, ensuring manageable risk levels for the guarantees provided [8] Total Guarantee Amount - After the new guarantees, the total guarantee amount by the company and its subsidiaries will be 2,538 million RMB, representing 183.61% of the latest audited net assets [9]